Diabetes mellitus (DM) represents a complicated metabolic disorder with an increasing global incidence, necessitating the identification of effective therapeutic agents. Out of the various approaches, heterocyclic pyrazoline derivatives have surfaced as promising candidates because of their extensive pharmacological properties, encompassing anti-diabetic, anti-inflammatory, and antioxidant characteristics. This review offers a thorough analysis of pyrazoline derivatives, emphasizing their mechanisms of action, including the inhibition of vital metabolic enzymes, enhancement of insulin sensitivity, and decrease in oxidative stress. Structure-activity relationship (SAR) investigations have illustrated the potential for specific modifications on the pyrazoline nucleus to enhance biological effectiveness. Additionally, recent progress in molecular docking and in vivo investigations underscores their therapeutic promise. In spite of its promise, more pharmacokinetic, pharmacodynamic, and clinical studies are essential to validate these compounds as effective anti-diabetic agents. This study integrates existing knowledge on pyrazolines and pinpoints future research directions, aiming to encourage novel diabetes treatment strategies.
A Sat, study studied this question.